Madrigal Pharmaceuticals Inc
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -1.6% | -100.0% | +49,259.0% | +24.7% | +16.7% | +320.5% | -14.0% | +15.3% | +12.8% | +32.1% | +577.6% | |
| – | -42.1% | +101.8% | -62.5% | +314.5% | +68.7% | -8.9% | +29.6% | +17.7% | +57.3% | +60.6% | +22.8% | |
| – | -42.1% | +84.4% | -59.0% | +314.5% | +68.7% | -8.9% | +29.6% | +17.7% | – | – | – | |
| – | – | – | – | -214.1% | – | +20.7% | +30.5% | +22.7% | -108.7% | – | – | |
| – | -59.7% | -94.7% | +3,958.4% | -82.4% | +681.8% | +94.2% | -37.4% | +3.8% | +581.6% | -1.1% | -68.1% | |
| – | – | +10.0% | -200.1% | +1,627.1% | – | +420.3% | -103.2% | – | -343.1% | -45.4% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -58.9% | -83.9% | +2,819.2% | +80.9% | -99.9% | – | – | – | – | – | – | |
| – | -2.5% | – | – | – | – | +0.0% | +0.0% | -1.8% | +32.3% | -100.0% | – | |
| – | -52.7% | -64.2% | +1,102.5% | +80.9% | -99.9% | +2,065.1% | +3,265.5% | +83.1% | +89.9% | +23.5% | -65.2% | |
| – | – | – | +587.3% | -170.5% | – | – | -342.7% | – | -178.4% | – | +1,835.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.